Table 1.
Characteristics of studies included in analysis
| Trial name or location, and year of trial start | Group size (intervention/ control)* | Follow-up (years) | Sex, age range (years) | Recruited from | Health checks | Included in mortality analyses | |||
|---|---|---|---|---|---|---|---|---|---|
| Performed at | Lifestyle intervention | No of checks | Uptake (%)† | ||||||
| Göteborg, Sweden 196319 | 1010/1956 | 15 | Men, 50 | Community | Hospital | No | 3 | 85 | Yes |
| Kaiser Permanente, USA 196526 | 5138/5536 | 16 | Men and women, 35-54 | Health plan members | Screening clinic | No | N/A‡ | N/A‡ | Yes |
| South east London, UK 196714 | 3292/3132 | 9 | Men and women, 40-64 | GP lists | Screening clinic | No | 2 | 73 | Yes |
| Northumberland, UK 196915 | 242/291 | 1½ | Men, 50-59 | GP lists | GP | No | 1 | 90 | No |
| Malmö, Sweden 196920 | 809/804 | 5 | Men, 55 | Community | Unclear, but not GP | No | 1 | 87 | Yes |
| Stockholm, Sweden 196921 | 3064/29 122 | 22 | Men and women, 18-65 | Community | Unclear, but not GP | No | 1 | 84 | Yes |
| Göteborg, Sweden 197022 | 10 004/20 018 | 11.8 | Men, 47-55 | Community | Unclear, but not GP | Yes | 2 | 75 | Yes |
| WHO, Europe 197127 | 30 489/26 971 | 5 to 6 | Men, 40-59 | Workplace | Workplace | Yes | 1 | 86 | Yes |
| Salt Lake City, USA 197223 | 642/454 | 1 | Men and women, ≥18 | Community | Screening clinic | No | 1 | 60 | No |
| Mankato, USA 198224 | 1156/1167 | 1 | Men and women, 25-74 | Community | Screening clinic | Yes | 1 | 50 | No |
| OXCHECK, UK 198916 | 8307/2783 | 4 | Men and women, 35-64 | GP lists | GP | Yes | 1-3 | ~80 | Yes |
| Family heart, UK 199017 | 3436/9488 | 1 | Men and women, 40-59 | GP lists | GP | Yes | 1 | 73 | No |
| Ebeltoft, Denmark 199218 | 2030/1434 | 8 | Men and women, 30-49 | GP lists | GP | Yes | 2 | 90 | Yes |
| Inter99, Denmark 199925 | 6784/3321§ | 5§ | Men and women, 30-60 | Community | Screening clinic | Yes | 2-4 | 53 | No |
GP=general practice.
*Groups merged in some trials.
†Uptake at first round.
‡This trial did not have screening rounds but continuous urging of the intervention group by written invitations and telephone calls to use a prepaid health check.
§Sample size of follow-up length for the analysis of self reported health. The trial was larger, with 13 016 participants randomised to health checks and 48 285 to control, followed for 10 years, but full results not yet published.